Structure Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Structure Therapeutics Inc's ROI in the second quarter of 2026?
Structure Therapeutics Inc recorded a cumulative net loss of $-215 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -16.83%.

Within the Healthcare sector 295 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3221, from total ROI ranking in the first quarter of 2026 at 3749.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	50.21 %	29.16 %	25.67 %	20.58 %	68.97 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	1,359	1,451	1,521	775	802
Return On Investment (TTM)	-16.83 %	-14.98 %	-14.38 %	-25.74 %	-21.06 %
GPCR's Overall Ranking	# 3221	# 3749	# 3530	# 3459	# 3369
Seq. Investment Change TTM	12.26 %	15.81 %	19.96 %	-3.68 %	-3.48 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-215	-170	-141	-211	-179

GPCR Company Profile >> Back to GPCR Roi Comparisons >> See Annual GPCR Return On Investment

Return On Investment GPCR's Ranking
Within:	No.
Industry	# 106
Sector	# 296
Overall	# 3221

Return On Investment Statistics
High	Average	Low
-14.38 %	-21.18 %	-32.46 %
(Dec 31 2025)		(Dec 31 2023)

Financial Statements
Structure Therapeutics Inc's II. Quarter Investments	$ 1,359 Millions	GPCR's Balance sheet
Structure Therapeutics Inc's II. Quarter Income	$ -106 Millions	Quarterly GPCR's Income Statement
GPCR's Income by Division		See GPCR's Income by Division

GPCR Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023
Total Investments in Millions	1,521	867	457	0	0
Y / Y Investment Growth	75.33 %	89.67 %	-	-	-
Net Income in Millions	-141	-123	-90	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-9.29 %	-14.13 %	-19.6 %	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GPCR's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GPCR's Competitors
Subscribers only: Roi for Structure Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for GPCR's Customers

Other Ratios
GPCR's Roa	GPCR's Inventory Turnover Ratio	GPCR's Growth Rates	GPCR's Dividend Statistics
	GPCR's Profitability Ratios	GPCR's Asset Turnover Ratio	GPCR's Dividend Growth
GPCR's Roe	GPCR's Valuation Ratios	GPCR's Financial Strength Ratios	GPCR's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-08T01:17:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.